Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned invasive strategy in terms of clinical outcomes.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Major Inclusion Criteria:
Hospitalization for an acute coronary syndrome (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction or unstable angina pectoris) with planned invasive strategy
Major Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
4,018 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal